The Sunbeam trial significantly reduced falls in long-term aged care (LTC) residents. The current study's primary objective was to undertake subgroup analysis of the Sunbeam trial, to determine whether the intervention was effective for reducing...
To describe potentially avoidable fall-related transfers to the emergency department (ED), and to identify infrastructure, training needs, and resources deemed appropriate for implementation in nursing homes (NHs) to decrease fall-related transfers...
On February 11, the Food and Drug Administration (FDA) authorized the emergency use of the monoclonal antibody bebtelovimab for the treatment of mild-to-moderate COVID-19 in adult and pediatric patients when all of these apply: They have a positive...
The Centers for Medicare & Medicaid Services (CMS) has posted new resources related to MIPS Value Pathways (MVPs) development on the QPP Resource Library . The following documents are now available in the MIPS Value Pathways (MVPs) Development...
As a reminder, the Centers for Medicare & Medicaid Services (CMS) and its contractor, Acumen, LLC, are conducting field testing of five episode-based cost measures until February 25 . The following episode-based cost measures are currently being...
Older adults with sarcopenic obesity have a higher risk of experiencing mobility difficulty. Additionally, sarcopenia and obesity are closely associated with knee osteoarthritis. This study investigated the associations of sarcopenia, obesity, and...
MEMBERS ONLY CONTENT Login or Join St. Louis-based Ascension Living, a mission-driven senior care and living provider with 28 skilled nursing facility medical directors across 11 states and Washington, DC, now requires all community medical...
Identifying patients in the palliative phase is challenging but important, as timely and proactive palliative care can improve quality of life.1 One way of determining whether a patient is in the palliative phase is via the Surprise Question, a...
This study aimed to determine the comparative effectiveness of interventions in treatment of sarcopenia. The primary outcome was the measure of treatment effect on muscle mass, and secondary outcomes were the treatment effect on muscle strength and...
